SHR-A1201
SHR-A1201 is a HER2-targeting antibody-drug conjugate (ADC). SHR-A1201 is composed of a humanized anti-HER2 antibody , a linker SMCC (HY-42360), and a microtubulin inhibitor payload Mertansine (HY-19792). SHR-A1201 can be used for research in HER2-positive breast cancer[1].
Product Specifications
UNSPSC
12352203
Target
Antibody-Drug Conjugates (ADCs) ; EGFR
Type
Reference compound
Related Pathways
Antibody-drug Conjugate/ADC Related; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/shr-a1201.html
Purity
97.35
Smiles
S[R][A1201]
References & Citations
[1]Xianjing Li, et al. Development and validation of pharmacokinetics assays for a novel HER2-targeting antibody-drug conjugate (SHR-A1201) : Application to its dose-escalation pharmacokinetic study. J Pharm Biomed Anal. 2024 Mar 15:240:115964.
Shipping Conditions
Dry Ice
Storage Conditions
-80°C, protect from light
Badge
Hot
Scientific Category
ADC Related
Clinical Information
No Development Reported
Isoform
ErbB2/HER2
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
IMSAHUCD83HB15ECPE200 200 Tests
Anti Human CD83 Flow Cytometry Monoclonal Clone HB15E PE Ready To Use 200 Tests
Sign In for Pricing
View Details